ARRIVENT BIOPHARMA INC (AVBP)
Health Care · Biotechnology · NASDAQ
Arrivent Biopharma is a clinical-stage oncology company dedicated to advancing a pipeline of innovative cancer therapies through global development and strategic in-licensing.
What ARRIVENT BIOPHARMA INC does
Arrivent Biopharma is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative therapies for patients with cancer. The company leverages a global business model to in-license and develop clinical-stage drug candidates, aiming to address significant unmet medical needs in oncology.
Themes: oncology drug development, clinical-stage biopharma, cancer therapeutics
Fundamentals
- Price$18.85 as of 2026-10-20 close
- Market cap$929M as of 2026-08-10 (share count; price 2026-10-20)
- 1-year return-5.7% 2025-10-20 close $19.99 → 2026-10-20 close $18.85
- P/En/a negative earnings
- ROE-54.1% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.97 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How AVBP compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$53M | -$50M | -$1.05 | -$40M† |
| Q1 FY2026 2026-03-31 | -$46M | -$43M | -$0.96 | -$42M |
| Q4 FY2025 2025-12-31 | -$39M† | -$36M† | -$0.78† | -$31M† |
| Q3 FY2025 2025-09-30 | -$38M | -$35M | -$0.83 | -$36M† |
| Q2 FY2025 2025-06-30 | -$34M | -$31M | -$0.90 | -$26M† |
| Q1 FY2025 2025-03-31 | -$67M | -$64M | -$1.90 | -$68M |
| Q4 FY2024 2024-12-31 | -$24M† | -$21M† | -$0.61† | -$16M† |
| Q3 FY2024 2024-09-30 | -$24M | -$21M | -$0.61 | -$16M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$155M
- Short-term investments$218M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ARRIVENT BIOPHARMA INC looks technically
ARRIVENT BIOPHARMA INC (AVBP) is trading 29.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 11 trading days ago. It is 47.4% below its highest point of the past year. Trading volume is unusually light — only about 49% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 29.8% below its 200-day average, the long-term trend line — a long-term downtrend | -29.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.83 | $26.83 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.85 | $26.85 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 27.28. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal | 1 session |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control | 33.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 36.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($11.36 to $30.64) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 38.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.83 | $35.83 |
|---|---|---|
| From the 52-week high | it is 47.4% below its 52-week high (its highest price of the past year) | -47.4% |
| Above the 52-week low | it is 65.9% above its 52-week low (its lowest price of the past year) | +65.9% |
| Below the 52-week high | it is 47.4% below its highest point of the past year | 47.4% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $36.37 (set on 2024-11-08) | $36.37 |
| Given back of the 52-week move | over the past year its closes ranged ($15.09 to $34.74), and it has recovered roughly a quarter of its fall from last year’s high — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $27.23 to $27.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.1% |
| From the all-time high | it is 48.2% below its all-time high | -48.2% |
| Nearest price level | it is trading 5.3% below a resistance level at $19.86 — a price it turned at twice since 2025-07-07, most recently on 2026-02-11. Since 2024-10-21 it has 1 such level below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.3% |
| All-time low | its lowest closing price on record is $11.36 (set on 2026-10-06) | $11.36 |
| Above the all-time low | it is 65.9% above its all-time low | +65.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.86 between its high and its low — about 9.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.86 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.82 and $34.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.82 – $22.40 – $34.98 |
| Typical daily range (% of price) | its price moves about 9.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.9% |
| Stretch from the 200-day average | it is trading 4.3 daily ranges below its 200-day average price (29.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 49% of its 30-day average | 0.49× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.9% since the prior reading | +4.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 57.5% below the previous close 10 sessions ago and has not traded back through the level it left behind at 28.46 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -57.5% |
| Gap filled | a 2.3% gap up opened on 2026-09-18 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 21 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +13.15% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 35.7 percentage points (the stock lost 34.8% while the market gained 1.0%) | -35.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 36.8 percentage points (the stock lost 33.2% while the market gained 3.6%) | -36.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 48.5 percentage points (the stock lost 39.9% while the market gained 8.5%) | -48.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 20.3 percentage points (the stock lost 5.7% while the market gained 14.6%) | -20.3% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 37% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -36.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $24.60 — a volume-weighted average of daily closes over 195 sessions, not a true tick-by-tick VWAP. | -23.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $20.85 — a volume-weighted average of daily closes over 49 sessions, not a true tick-by-tick VWAP. | -9.6% |
Price levels it has turned at before
AVBP last closed at $18.85 on 2026-10-20. Since 2024-10-21 it has turned at 1 price below its last close and 10 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.86 | Resistance | 5.3% above the last close | turned there twice · 2025-07-07 to 2026-02-11 |
| $20.60 | Resistance | 9.3% above the last close | turned there three times · 2025-12-03 to 2026-03-30 |
| $17.08 | Support | 9.4% below the last close | turned there three times · 2025-09-17 to 2025-11-03 |
| $21.13 | Resistance | 12.1% above the last close | turned there three times · 2025-03-04 to 2025-09-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $27.28.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $16.11 and $21.43 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $11.36.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$21.56 range $15.00 – $29.00; median $20.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVBP
- Consensus EPS estimate-$1.08 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.00363 from -$1.07, on 2026-09-15, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is a clinical-stage entity with a history of significant operating losses and expects these losses to continue.","Success is dependent on the clinical development and regulatory approval of its lead drug candidates, which may fail or face delays."]
What changed in the latest 10-Q
AI-assisted comparison of AVBP's 10-Q filed 2026-08-12 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) adds a paragraph describing receipt of an FDA Breakthrough Therapy Designation for ARR-002, a MUC16/NaPi2b dual-targeting tetravalent ADC, with an initial focus on ovarian and endometrial cancers; it states the Phase 1 trial has been initiated with the first patient expected to be dosed in the second half of 2026.
- Newer filing (2026-08-12) adds a sentence noting that the 79% tumor-size reduction in the FAVOUR interim data readout was 'as measured by blinded independent central review utilizing Response Evaluation Criteria in Solid Tumors 1.1 criteria' in the first paragraph describing the interim data readout.
- Newer filing (2026-08-12) adds language to the FURTHER final analysis paragraph noting 'Interim results may not be indicative of final results; however, we believe these interim clinical results underscore firmonertinib's potential in patients whose tumors contain an uncommon EGFRm.'
- Removed:
- Older filing (2026-05-11) contains a paragraph at the end of the 'As one of the most prevalent cancers...' section repeating the FAVOUR interim data readout with additional detail about the threshold being for partial response and inclusion in ORR determination, which is removed in the newer filing.
- Older filing (2026-05-11) includes a sentence in the repeated FAVOUR interim data readout paragraph stating 'This measurement of reduction is the threshold in this trial for a partial response and for inclusion in determination of the overall response rate (ORR), which is the primary endpoint of this trial.' This sentence does not appear in the newer filing.
- Reworded:
- Newer filing (2026-08-12) changes 'ARR 217 (MRG007)' to 'ARR-217 (“MRG007”)'.
- Newer filing (2026-08-12) changes 'epidermal growth factor receptor mutant (EGFRm)' to 'epidermal growth factor receptor mutations (“EGFRm”)'.
- Newer filing (2026-08-12) changes 'in first-line patients with locally advanced or metastatic EGFRm NSCLC with PACC mutations' to 'in first-line patients with locally advanced or metastatic EGFRm NSCLC with P-loop and alpha-c-helix compressing (“PACC”) mutations'.
- Newer filing (2026-08-12) changes 'Breakthrough Therapy Designation' first mention formatting from plain text to 'Breakthrough Therapy Designation (“BTD”)' and the later description from 'A product candidate can receive Breakthrough Therapy Designation' to 'A product candidate can receive BTD'.
- Newer filing (2026-08-12) changes 'United States Food and Drug Administration (FDA)' to 'United States Food and Drug Administration (“FDA”)'.
- Newer filing (2026-08-12) changes 'epidermal growth factor receptor (EGFR)' to 'epidermal growth factor receptor (“EGFR”)'.
- Newer filing (2026-08-12) changes 'tyrosine kinase inhibitor (TKI)' to 'tyrosine kinase inhibitor (“TKI”)'.
- Newer filing (2026-08-12) changes 'Shanghai Allist Pharmaceuticals Co. Ltd. (Allist)' to 'Shanghai Allist Pharmaceuticals Co. Ltd. (“Allist”)'.
- Newer filing (2026-08-12) changes 'EGFRm exon20 NSCLC' to 'EGFRm exon 20 NSCLC'.
- Newer filing (2026-08-12) changes 'EGFR P-loop and-alpha-c-helix compressing (PACC) mutations' to 'EGFR PACC mutations' in the selection rationale sentence.
- Newer filing (2026-08-12) changes 'median progression free survival' to 'median progression-free survival'.
- Newer filing (2026-08-12) changes 'duration of response (DOR) 14.6 months' to 'DOR 14.6 months'.
- Newer filing (2026-08-12) changes 'confirmed central nervous system responses with firmonertinib including complete responses' to 'confirmed central nervous system responses with firmonertinib, including complete responses'.
- Newer filing (2026-08-12) changes the FAVOUR repeated paragraph from '...were observed to experience a reduction in tumor size of at least 30% from the baseline in a patient without evidence of progression as measured by blinded independent central review utilizing Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria' to '...were observed to experience a reduction in tumor size of at least 30%, as measured by blinded independent central review utilizing Response Evaluation Criteria in Solid Tumors 1.1 criteria'.
- Newer filing (2026-08-12) changes the Investor Relations website URL description from 'the Investors section of our website' to 'the Investor Relations section of our website'.
- Newer filing (2026-08-12) changes 'the audited financial information and the notes thereto included in our Annual Report on Form 10-K for fiscal year ended December 31, 2025' to 'the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025'.
- Notes:
- The newer filing text ends mid-sentence ('...secured an exclusive, royalty bearing and sublicensable license under certai') and the older filing text ends mid-sentence ('...Global Technology Transfer and License Agree'), so comparison beyond those points is limited to available text.
- The newer filing includes an FDA IND clearance announcement for ARR-002 dated May 2026, which is not present in the older filing.
- The older filing contains repeated FAVOUR interim data readout language that appears redundant with earlier text, which the newer filing condenses.
Risk Factors
- Added:
- In the filing dated 2026-08-12, added a new risk factor titled 'Issued patents covering our current product candidates or our future product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.'
- In the filing dated 2026-08-12, added the statement: 'In July 2026, we received a notice from the USPTO that the USPTO has granted the Request of the RE ’687 Patent.'
- In the filing dated 2026-08-12, added the statement: 'We believe the Request lacks merit and will vigorously defend the patentability of the claims of the RE ’687 Patent during ex parte reexamination.'
- In the filing dated 2026-08-12, added the statement: 'We cannot predict the outcome of the ex parte reexamination proceeding, which could result in all or some of the claims being confirmed as patentable, narrowed, or cancelled as deemed unpatentable.'
- In the filing dated 2026-08-12, added the statement: 'If we are unsuccessful in defending the RE ‘687 Patent and the claims of the RE ‘687 Patent are narrowed or cancelled during ex parte reexamination, it could have a material adverse effect on our business, financial condition, results of operations and prospects.'
- In the filing dated 2026-08-12, added the statement: 'Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.'
- In the filing dated 2026-08-12, added a paragraph beginning with 'If we or our licensors initiate legal proceedings against a third party to enforce a patent covering our current product candidates or any of our future product candidates, the defendant could counterclaim that such patent is invalid or unenforceable.'
- Removed:
- In the filing dated 2026-05-11, the exhibit list included Exhibit 10.1* 'Amendment No. 1 to Loan and Security Agreement, dated March 5, 2026, by and between Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, and the Registrant'; this exhibit is not present in the 2026-08-12 exhibit list.
- In the filing dated 2026-05-11, footnotes reading '* Filed with this Quarterly Report on Form 10-Q.' and the paragraph about Exhibit 32.1 and 32.2 certifications were present after the exhibit list; these are not present in the 2026-08-12 filing.
- In the filing dated 2026-05-11, a SIGNATURES section with signatures by Zhengbin (Bing) Yao and Winston Kung dated May 11, 2026 was present; this section is not present in the 2026-08-12 excerpt.
- Reworded:
- Introductory sentence: 2026-05-11 said 'There have been no additional material changes to our risk factors'; 2026-08-12 says 'Other than as described below, there have been no additional material changes to our risk factors'.
- Issuer Purchases of Equity Securities: 2026-05-11 referenced 'the three months ended March 31, 2026'; 2026-08-12 references 'the quarter ended June 30, 2026'.
- Rule 10b5-1 Trading Plans: 2026-05-11 referenced 'the fiscal quarter ended March 31, 2026'; 2026-08-12 references 'the fiscal quarter ended June 30, 2026'.
- Exhibits heading for 101.INS: 2026-05-11 had 'Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.'; 2026-08-12 has the same description but the 2026-05-11 version included 'information contained in Exhibits 101' in Exhibit 104 description, while 2026-08-12 truncates the Exhibit 104 description.
- Notes:
- The newer filing excerpt appears truncated mid-sentence in the Exhibit 104 description ('formatted as Inline XBRL with applicable taxonomy extension'), so not all differences in the exhibit list footnote region are assessable.
- The comparison uses only the provided source text excerpts; other parts of the SEC filings were not compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Most recent open-market transaction: 2025-12-10. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVBP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AVBP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 8,199,025
- Reported value $284,834,126
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVBP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVBP had 8,451,472 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AVBP had 17.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.25 days to cover at the same settlement.
- Reported short interest (shares) 8,451,472
- Short interest (% of shares outstanding) 17.1%
- Prior settlement (shares) 8,766,246
- Reported change -3.59%
- Days to cover (reported) 11.25
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Merck & Co. (MRK)
- Pfizer (PFE)
- Roche (RHHBY)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVBP vs…
ARRIVENT BIOPHARMA INC is found in…
Frequently asked questions
What does ARRIVENT BIOPHARMA INC (AVBP) do?
Arrivent Biopharma is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative therapies for patients with cancer. The company leverages a global business model to in-license and develop clinical-stage drug candidates, aiming to address significant unmet medical needs in oncology.
What sector is ARRIVENT BIOPHARMA INC (AVBP) in?
ARRIVENT BIOPHARMA INC (AVBP) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ARRIVENT BIOPHARMA INC's (AVBP) competitors?
Notable peers of ARRIVENT BIOPHARMA INC (AVBP) include AstraZeneca, Merck & Co., Pfizer, Roche and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is ARRIVENT BIOPHARMA INC (AVBP) overbought or oversold right now?
ARRIVENT BIOPHARMA INC (AVBP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVBP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.